Last updated: March 2, 2026
What is NDC 42291-0048?
NDC 42291-0048 refers to a specific formulation of a pharmaceutical product. According to the FDA’s National Drug Code Directory, this code corresponds to Xyrem (sodium oxybate) oral solution used to treat narcolepsy with cataplexy. It is a Schedule III controlled substance primarily distributed by Jazz Pharmaceuticals.
Market Overview
Indications and Market Size
- Approved Uses: Treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy.
- Market Size: The global narcolepsy treatment market is valued at approximately $250 million in 2022. Xyrem accounts for roughly 70% of this market share, driven by the drug’s exclusivity status and therapeutic profile.
- Market Dynamics: The demand is driven by increased awareness of narcolepsy, improved diagnostic techniques, and limited alternative therapies.
Competition and Alternatives
- Main Competitors: Other sodium oxybate formulations, off-label sleep aids, and stimulants (e.g., modafinil, armodafinil).
- Market Share: Xyrem holds a dominant position due to its FDA approval for narcolepsy with cataplexy and a patent-protected formulation.
- Emerging Treatments: Upcoming therapies include lower-schedule formulations, behavioral interventions, and novel pharmacologic agents like hydroxynaphthoate derivatives.
Regulatory and Reimbursement Landscape
- Patents and Exclusivity: The original patent expires in 2030, with some legal protections anticipated to extend through secondary patents until 2035.
- Reimbursement: Medicaid and private insurers generally cover Xyrem, with co-pays ranging from $50 to $300 monthly, subject to insurance policies.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 30mL |
Estimated Monthly Cost |
| 2018 |
$2,900 |
$2,900 |
| 2019 |
$2,950 |
$2,950 |
| 2020 |
$3,000 |
$3,000 |
| 2021 |
$3,200 |
$3,200 |
| 2022 |
$3,400 |
$3,400 |
Note: Prices increased approximately 4-6% annually, aligning with inflation, inflation-adjusted drug shortages, and market exclusivity.
Future Price Projections (2023-2027)
Considering current market trends, patent protections, and negotiations:
| Year |
Projected AWP per 30mL |
Key Factors |
| 2023 |
$3,600 |
Slight price increase; potential biosimilar presence unlikely due to regulatory hurdles. |
| 2024 |
$3,700 |
Rising manufacturing costs, high demand. |
| 2025 |
$3,800 |
Extended patent exclusivity; no biosimilar entry expected. |
| 2026 |
$3,900 |
Slight price stabilization as competition remains minimal. |
| 2027 |
$4,000 |
Inflation adjustment; market stability persists. |
Price Drivers
- Regulatory Exclusivity: Patent rights protect pricing until at least 2030.
- Manufacturing Costs: Higher due to raw material inflation and handling of Schedule III substances.
- Market Demand: Increased awareness supports stable or rising prices.
- Biosimilar Entry: Unlikely before 2030, which limits downward pricing pressure.
Strategic Insights
- Pricing Power: Jazz Pharmaceuticals can sustain or modestly increase prices through market exclusivity and limited competition.
- Market Expansion: Limited to narcolepsy; off-label use or broader sleep disorder applications are research areas but face regulatory and safety hurdles.
- Potential Risks: Biosimilar development or regulatory changes could pressure prices after patent expiry.
Summary of Key Data Points
- Market Size (2022): ~$175 million for Xyrem globally.
- Current Price Range: $3,200–$3,400 per 30mL bottle.
- Patent Expiry: 2030 for core patents, with secondary patent protections likely until 2035.
- Price Projections (2023-2027): Incremental increases, reaching ~$4,000 per 30mL by 2027.
Key Takeaways
- NDC 42291-0048, corresponding to Xyrem, dominates narcolepsy therapy with high market share and pricing power.
- Pricing has steadily increased, with limited pressure from biosimilars until patent expiration.
- Market size remains stable, with future growth driven by increased diagnosis and prescription rates.
- Patents and regulatory exclusivity are the primary factors supporting sustained prices through at least 2030.
- Competitive threats from biosimilar products hinge on regulatory and legal developments, but are unlikely before patent expiry.
FAQs
1. When do patents for Xyrem expire?
Patent protections typically extend until 2030, with secondary patents potentially extending market exclusivity until 2035.
2. What are the main drivers behind the price increase of NDC 42291-0048?
Rising manufacturing costs, high demand, limited competition, and patent protections support price increases.
3. Will biosimilars or generics impact pricing?
Biosimilars are unlikely before 2030 due to regulatory complexity; generics are incompatible with the drug’s formulation.
4. How does reimbursement affect market dynamics?
Insurance coverage generally mitigates patient cost sensitivity, allowing sustained pricing. Co-pays are relatively stable.
5. Are there upcoming regulatory changes that could influence prices?
Potential changes include patent challenges or regulatory approvals for alternative formulations; however, no significant changes are anticipated before patent expiry.
References
[1] U.S. Food and Drug Administration. (2023). National Drug Code Directory.
[2] IQVIA. (2022). Market Analysis for Narcolepsy Treatments.
[3] Jazz Pharmaceuticals. (2022). Xyrem Prescribing Information.
[4] FDA. (2022). Patent and Exclusivity Data.
[5] MarketWatch. (2022). Narcolepsy Treatment Market Outlook.
